LeMaitre Vascular assumes EU MDR CE Mark responsibility for CardioCel/VascuCel; costs deducted from $2M earn-out

LEMAITRE VASCULAR INC

On August 28, 2021, LeMaitre amended its 2019 asset purchase agreement with Anteris Technologies (formerly Admedus).
LeMaitre will seek CE Mark certification under EU MDR for CardioCel and VascuCel biologic patches.
Costs of obtaining CE Mark approvals will be deducted from the $2 million earn-out payable to Anteris.
75% of earn-out paid after CardioCel MDR certification; 25% after VascuCel MDR certification.
Transition services agreement extended by nine months to July 11, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.